The Senate Health, Education, Labor and Pensions Committee is set to consider the Medication Affordability and Patent Integrity Act this week, a bill that critics argue would increase regulatory burdens on biotech companies without actually lowering prescription drug prices. Despite its name, the legislation does little to address the core issue of drug affordability, instead adding new compliance requirements that could slow the development of new treatments.
Lawmakers are pushing the bill in response to long-standing public frustration over high drug costs, especially in an election year. The bill's title—emphasizing "medication affordability" and "patent integrity"—plays well in campaign ads, but experts say it won't make brand-name medicines more accessible. Instead, it would require drug companies to provide additional certifications and disclosures to both the U.S. Food and Drug Administration and the U.S. Patent and Trademark Office, aiming to align information between the two agencies. However, these agencies serve different purposes and require different data; the Patent Office doesn't need clinical trial outcomes that the FDA mandates.
The bill would also allow generic drug companies to challenge pharmaceutical patents in court by alleging that brand-name manufacturers failed to comply with the new requirements. Supporters claim that pharmaceutical companies exploit patent system loopholes to delay generic competition, but evidence of such abuse is scant. America already has the highest generic drug utilization rate globally, with about 90% of prescriptions filled as generics or biosimilars. The average brand-name drug spends roughly 13 years on the market before generics arrive, a figure that has remained stable for decades.
Brand-name companies do sometimes seek additional patents after a drug's release, but these often stem from new research that improves the drug or enhances patient compliance. For instance, GLP-1 drugs for diabetes, now also used for weight loss, started as injectables; companies are developing pill forms that could be easier for patients to take. These improvements may warrant new patents, even as some injectables go off patent. Innovation doesn't stop at FDA approval, and continued research benefits patients.
Existing law already penalizes patent misconduct: applicants who deceive examiners face severe penalties, and courts can render patents unenforceable in cases of fraud. Critics question why lawmakers need a new compliance regime when current remedies are sufficient. Washington often assumes more reporting and oversight will lower prices, but increasing red tape historically has the opposite effect. The current regulatory environment already contributes to high drug costs.
The Patent Office takes nearly three years on average to decide patent applications; additional disclosures could further strain the system. Every new disclosure obligation raises compliance costs, legal exposure, and uncertainty, influencing where investment flows. Pharmaceutical innovation is extraordinarily expensive and risky—researchers often spend years on promising treatments, like those for Alzheimer's, only to see them fail in clinical trials. Companies routinely invest hundreds of millions or billions in projects that never reach the market.
If drug companies fear losing patent protections due to paperwork issues, they may cut research and development, ceding America's role as a global drug innovator. Patients would ultimately pay the price. While Americans deserve affordable medicines, they also need a system that incentivizes investment in new treatments despite high failure risks. The Medication Affordability and Patent Integrity Act would make the drug-approval process more challenging, not better.
This debate comes as former President Trump expands his drug price platform, and as House Democrats craft an agenda focused on affordability. The bill's fate remains uncertain amid broader discussions on healthcare costs.
